医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

WaVe Life Sciences Appoints Roberto Guerciolini, M.D., as Senior Vice President and Head of Early Development

2015年04月07日 PM09:00
このエントリーをはてなブックマークに追加


 

BOSTON & OKINAWA, Japan

WaVe Life Sciences today announced that Roberto Guerciolini, M.D., has been appointed as Senior Vice President and Head of Early Development. He was most recently Vice President and Product General Manager at Shire and brings tremendous biopharmaceutical research and development experience from lead identification through clinical development across multiple therapeutic areas. Dr. Guerciolini will lead WaVe Life Sciences’ translational and early clinical activities as the company advances a pipeline of stereopure nucleic acid drug candidates across multiple disease areas.

“The addition of Dr. Guerciolini to our team continues WaVe’s trend of attracting extremely talented and accomplished individuals to our organization. He joins Dr. Chandra Vargeese, former head of RNA chemistry and delivery at Novartis and his former colleague at Sirna, where she was Vice President and head of chemistry. Chandra began leading WaVe’s drug discovery efforts in August,” said Paul Bolno, M.D., President and Chief Executive Officer of WaVe Life Sciences. “Roberto’s incredible clinical and regulatory perspective is critical to enhancing the success of our early program selection and development; he will be instrumental in accelerating our Company’s transition from research to development.”

“WaVe is tackling the limitations inherent to complex mixtures of oligonucleotides, and the Company’s platform for rational drug design and precise chemical synthesis is infinitely applicable across antisense, siRNA, mRNA, microRNA and beyond,” said Dr. Guerciolini. “While the possibilities seem endless, WaVe is focused on very important applications and building a pipeline that will demonstrate the revolutionary potential of stereopure nucleic acid therapeutics to address important human diseases.”

At Shire AG, a division of Shire plc in Switzerland, Dr. Guerciolini was responsible for building an early-stage pipeline for its Specialty Pharmaceuticals group. Prior to Shire, he was Senior Vice President of Pharmaceutical Development at Dicerna, a company which he co-founded. Previously, he was Senior Vice President of Development and Chief Medical Officer of Sirna Therapeutics, which was acquired by Merck & Co. in 2006. At Sirna, he led clinical development activities and regulatory affairs, conducting the first ever clinical trial with a chemically optimized siRNA. Prior to Sirna, he was Senior Director of Clinical Pharmacology and Experimental Medicine at Millennium Pharmaceuticals, where he was responsible for overseeing the conduct of early stage clinical trials in the areas of oncology, inflammation and metabolic diseases. While at Millennium, he also significantly contributed toward the successful filing of an NDA for VELCADE®. Prior to this, he served in clinical development at Roche, where he played an important role in the filing and registration of XENICAL® in the U.S. and Europe, as well as at Schering-Plough Corporation. Dr. Guerciolini received his Medical degree and Board certification in Internal Medicine from the University of Perugia Medical School in Italy. He completed a postdoctoral fellowship in Clinical Pharmacology at the Mayo Clinic and is certified by the American Board of Clinical Pharmacology. Dr. Guerciolini additionally earned an executive MBA from the Haas School of Business, University of California-Berkeley.

About WaVe Life Sciences

WaVe Life Sciences is leading a revolution in nucleic acid therapeutics and was founded on the core principle that medicines should possess precisely controlled molecular structures. We and our strategic partners are advancing a portfolio of stereopure drug candidates that target underlying biology across a wide range of human diseases. www.wavelifesciences.com

CONTACT

MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com
or
Charles
Liles, 781-235-3060
cliles@macbiocom.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作
  • ベルタンとザイモリサーチが新しい連携を発表
  • The First China (Chongqing) Selenium Enrichment Industry Development Conference, Organized by the Chongqing Jiangjin Agriculture Commission, Was Held in Jiangjin